EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Ruxolitinib in Dermatology: A Review of its Uses in Cutaneous Disorders

Neerja Saraswat, Durga Madhab Tripathy, Shekhar Neema, Santanu Banerjee, Vikas Pathania, Sushil Kumar, Anirudh Tripathy

Indian Journal of Dermatology · 2026-11 · 71 (6) · 423-433

DOI: 10.4103/ijd.ijd_504_25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Dermatology, online erschienen am 30.10.2026. Verfasst von Neerja Saraswat und 6 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, Military Hospital, Udhampur, Jammu and Kashmir, India. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies have highlighted the role of the JAK/STAT signalling pathway in chronic skin conditions such as atopic dermatitis, vitiligo, alopecia areata, lichen planus, and various granulomatous disorders like sarcoidosis, necrobiosis lipoidica, and granuloma annulare. Ruxolitinib is a first-generation JAK inhibitor that the US Food and Drug Administration approved for treating intermediate or high-risk myelofibrosis in 2011. Recently, the topical formulation has been approved to manage mild to moderate atopic dermatitis and non-segmental vitiligo in adults. Encouraging results have been demonstrated with topical ruxolitinib in multiple other skin diseases. This review provides a comprehensive analysis of the use of ruxolitinib in dermatological conditions through a PubMed literature search.

Schlagwörter

Stichwörter der Autor:innen

Alopecia areataJanus Kinase receptor pathwayRuxolitinibatopic dermatitisvitiligo

Autor:innen und Institutionen

  • From the Department of Dermatology, Military Hospital, Udhampur, Jammu and Kashmir, India.
  • Department of Dermatology, Military Hospital, Agra, India.
  • Department of Dermatology, Base Hospital, Lucknow, Uttar Pradesh, India.
  • Department of Dermatology, AFMC, Pune, Maharashtra, India.
  • Department of Dermatology, Motilal Nehru Medical College, Prayagraj, Uttar Pradesh, India.
  • Department of Microbiology, ABVIMS and Dr RML Hospital, New Delhi, India.

Zitieren

APA

Saraswat, N., Tripathy, D. M., Neema, S., Banerjee, S., Pathania, V., Kumar, S., & Tripathy, A. (2026). Ruxolitinib in Dermatology: A Review of its Uses in Cutaneous Disorders. Indian Journal of Dermatology, 71(6), 423-433. https://doi.org/10.4103/ijd.ijd_504_25

Vancouver

Saraswat N, Tripathy DM, Neema S, Banerjee S, Pathania V, Kumar S, et al. Ruxolitinib in Dermatology: A Review of its Uses in Cutaneous Disorders. Indian Journal of Dermatology. 2026;71(6):423-433. doi:10.4103/ijd.ijd_504_25

BibTeX
@article{Saraswat2026,
  author = {Saraswat, Neerja and Tripathy, Durga Madhab and Neema, Shekhar and Banerjee, Santanu and Pathania, Vikas and Kumar, Sushil and Tripathy, Anirudh},
  title = {Ruxolitinib in Dermatology: A Review of its Uses in Cutaneous Disorders},
  journal = {Indian Journal of Dermatology},
  year = {2026},
  volume = {71},
  number = {6},
  pages = {423--433},
  doi = {10.4103/ijd.ijd_504_25}
}
Kostenlos starten →